Supplement Tables

Table 1. Supplement Risk of bias assessment

Checklist	Chon S	Miao Y	Yoshida K	Kim HS	Feng Z	Zhang W	Wang Y	Williams K	Raungkaewmanee S	Asher V	Cho HB	EO WK
Selection												
Representativeness of exposed cohort	*	*	*	*	*	*	*	*	*	*	*	*
Selection of non exposed cohort	*	*	*	*	*	*	*	*	*	*	*	*
Ascertainment of exposure	*	*	*	*	*	*	*	*	*	*	*	*
Non presence of outcome at beginning	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Comparability												
Comparability of cohorts	**	**	**	**	**	**	**	*	**	**	**	**
Outcome												
Assessment of outcome	*	*	*	*	*	*	*	*	*	*	*	*
Enough follow-up time	*	*	*	*	*	*	*	*	*	*	*	

Adequacy of follow up	*	*	*	*	*	*	*	*	*	*	*

Cont' Table 1. Supplement Risk of bias assessment

Checklist	Kim YJ	Supoken A	Kwon	Badora Rybika
Selection				
representativeness of exposed cohort	*	*	*	*
Selection of non exposed cohort	*	*	*	*
Ascertainment of exposure	*	*	*	*
Non-presence of outcome at beginning	NA	NA	NA	NA
Comparability				
Comparability of cohorts	**	**	*	**
Outcome				
Assessment of outcome	*	*	*	*
Enough follow-up time		*		

Adequacy of follow up	*

Table 2. Base Characteristic of NLR Parameter Studies

Author	Year	Country	Study Type	Total Patients	Marker	Cut Off	Age (Years)	FIGO Stage	Follow up (Months)	Treatment
Miao Y	2016	China	Retrospective	344	NLR	3.02	55	III	72	6 cycles of Carboplatin + Oaclitaxel every 3 weeks
Yoshida K	2019	Japan	Retrospective	83	NLR	3.26	53	I , II, III	64.1	6 cycles Carboplatin + Paclitaxel every 3 weeks
Kim HS	2015	Republic of Korea	Retrospective	109	NLR	2.4	53	I, II, III, IV	46	NA
Feng Z	2016	China	Retrospective	875	NLR	NLR: 3.24	56	I, II, III, IV	29	Platinum based Chemotherapy
Zhang W	2015	China	Retrospective	190	NLR	3.4	50.6	I, II, III, IV	43	Platinum based Chemotherapy
Wang Y	2014	China	Retrospective	126	NLR	3.77	50	I, II, III, IV	41.3	Platinum based Chemotherapy
Williams KA	2014	USA	Retrospective	519	NLR	NLR: 3.6	50	I, II, III, IV	68.4	NA
Raungkaewmanee S	2012	Thailand	Retrospective	196	NLR	2.6	53	I, II, III, IV	28.3	NA

Asher V	2010	United Kingdom	Retrospective	235	NLR	4.49	62	I, II, III, IV	60	Platinum based Chemotherapy
Cho HB	2009	Republic of Korea	Retrospective	192	NLR	NLR: 2.6	51.8	I, II, III, IV	20.9	NA
EO WK	2016	Republic of Korea	Retrospective	234	NLR	4.28	54	I, II, III, IV	NA	NA
Kim YJ	2018	Republic of Korea	Retrospective	197	NLR	3.81	57	III, IV	NA	Taxane + Platinum based chemo
Badora-Rybicka A	2016	Poland	Retrospective	315	NLR	2.96	54	I, II, III, IV	NA	NA
Kwon	2018	Republic of Korea	Retrospective	109	NLR	2.3	50	I, II, III, IV	NA	Platinum based Chemotherapy

Table 3. Base Characteristic of PLR Parameter Studies

Author	Year	Country	Study Type	Total Patients	Marker	Cut Off	Age (Years)	FIGO Stage	Follow up (Months)	Treatment
Chon S	2020	Republic of Korea	Retrospective	102	PLR	226	58	III, IV	41	NA
Miao Y	2016	China	Retrospective	344	PLR,	207	55	III	72	6 cycles of Carboplatin + Oaclitaxel every 3 weeks
Yoshida K	2019	Japan	Retrospective	83	PLR	165	53	I , II, III	64.1	6 cycles Carboplatin + Paclitaxel every 3 weeks
Kim HS	2015	Republic of Korea	Retrospective	109	PLR	205.4	53	I, II, III, IV	46	NA
Zhang W	2015	China	Retrospective	190	PLR	203	50.6	I, II, III, IV	43	Platinum based Chemotherapy
Wang Y	2014	China	Retrospective	126	PLR	243.7	50	I, II, III, IV	41.3	Platinum based Chemotherapy
Raungkaewmanee S	2012	Thailand	Retrospective	196	PLR	200	53	I, II, III, IV	28.3	NA
Asher V	2010	United Kingdom	Retrospective	235	PLR	267.1	62	I, II, III, IV	60	Platinum based Chemotherapy
EO WK	2016	Republic of Korea	Retrospective	234	PLR	246.8	54	I, II, III, IV	NA	NA

Badora-Rybicka A	2016	Poland	Retrospective	315	PLR	129.78	54	I, II, III, IV	NA	NA
Supoken A	2014	Thailand	Retrospective	36	PLR	300	52	I, II, III, IV	36	Paclitaxel + carboplatin
Kwon	2018	Republic of Korea	Retrospective	109	PLR	123.6	50	I, II, III, IV	NA	Platinum based Chemotherapy

Table 4. Histology Characteristic

Author	Year	FIGO Stage	Histology		
			Serous	Mucinous	Other
Chon S	2020	III, IV	75	4	23
Miao Y	2016	III	216	NA	128
Kim HS	2015	I, II, III, IV	5	NA	104
Zhang W	2015	I, II, III, IV	101	12	77
Williams KA	2014	I, II, III, IV	360	54	105
Raungkaewmanee S	2012	I, II, III, IV	58	30	108
Asher V	2010	I, II, III, IV	117	35	83
Cho HB	2009	I, II, III, IV	45	40	107
EO WK	2016	I, II, III, IV	132	35	76
Kim YJ	2018	III, IV	180	NA	17

Table 5. Characteristic of the Outcome in NLR Parameter

Author	Year	Overall Survival (Months)		5 Y Overall Survival (%)		Progression Free Survival (Months)		5 Y Progression Free Survival (%)	
		NLR High	NLR Low	NLR High	NLR Low	NLR High	NLR Low	NLR High	NLR Low
Yoshida K	2019	NA	NA	80.2	95.6	NA	NA	NA	NA
Feng Z	2016	45	69	NA	NA	16	21	NA	NA

Raungkaewmanee S	2012	NA	NA	58.8	63	NA	NA	52	55.7
Asher V	2010	15.6	43.1	NA	NA	NA	NA	NA	NA
Cho HB	2009	44.9	56.5	45	88	23.6	31.4	38	44
Kwon	2018	NA	NA	51.4	90.7	NA	NA	47.2	83

Table 6. Characteristic of the Outcome in PLR Parameter

Author	Year	Overall Survival (Months)		5 Y Overall Survival (%)		Progression Free Survival (Months)		5 Y Progression Free Survival (%)	
		PLR High	PLR Low	PLR High	PLR Low	PLR High	PLR Low	PLR High	PLR Low
Chon S	2020	40.2	49.9	46.3	66.7	25.4	34.7	24.1	35.4
Yoshida K	2019	NA	NA	84.3	96.7	NA	NA	86.9	74.2
Zhang W	2015	28	64	NA	NA	11	24	NA	NA
Raungkaewmanee S	2012	21.8	60.7	48	71.1	11.5	19.4	45	60.7
Asher V	2010	14.5	37.4	NA	NA	NA	NA	NA	NA
Supoken A	2014	NA	NA	NA	NA	10	34	NA	NA